Picture of Fortune Brands Innovations logo

FBIN — Fortune Brands Innovations News Story

0.000.00%
us flag iconLast trade - 00:00
Consumer CyclicalsBalancedLarge CapSuper Stock

Fortune Brands Q3 revenue misses estimates on execution issues

Fortune Brands Q3 revenue misses estimates on execution issues


Overview

  • Home, security and digital products firm's Q3 revenue fell 3% yr/yr, missing analyst expectations

  • Adjusted EPS for Q3 beat analyst expectations, aided by tax and tariff benefits

  • Company taking portfolio actions, including Fiberon sale and China exit


Outlook

  • Company expects Q4 net sales of $925 mln to $995 mln

  • Fortune Brands sees 2026 full-year EPS before charges/gains of $3.20 to $3.30

  • Company expects softness in single-family new construction and R&R in 2026


Result Drivers

  • EXECUTION AND ORGANIZATIONAL CHANGES - Co said execution issues weighed on results but cited recent improvements in service levels and leadership changes to strengthen performance

  • PORTFOLIO OPTIMIZATION - Co said actions to sell Fiberon, exit China and rationalize EMEA Water operations are aimed at removing loss-making businesses


Company press release: ID:nBwbyXt9Pa


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Miss

$1.10 bln

$1.12 bln (18 Analysts)

Q3 Adjusted EPS

Beat

$1.14

$0.74 (18 Analysts)

Q3 EPS

$0.42


Analyst Coverage

  • The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 8 "strong buy" or "buy", 11 "hold" and 1 "sell" or "strong sell"

  • The average consensus recommendation for the construction supplies & fixtures peer group is "buy."

  • Wall Street's median 12-month price target for Fortune Brands Innovations, Inc. is $48.50, about 4.1% above its November 2 closing price of $46.57

  • The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 15 three months ago


Reuters Recommended Reads

  • Nov 2 - Marriott lifts annual room revenue growth forecast on resilient travel demand

  • Nov 2 - Estee Lauder cuts promotions as luxury fragrances help lift outlook

  • Nov 3 - Pfizer raises 2026 forecasts as Eliquis, cancer drugs drive third-quarter results


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Fortune Brands Innovations

See all news